Opthea's Pivotal Phase 3 Trials For Sozinibercept In Wet AMD Completes Enrollment, Topline Results Anticipated Mid-2025
Portfolio Pulse from Benzinga Newsdesk
Opthea has completed enrollment for its Phase 3 trials of Sozinibercept in treating wet AMD, with topline results expected in mid-2025. The trials aim to replicate the positive visual outcomes seen in Phase 2b.
May 28, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Opthea has completed enrollment for its Phase 3 trials of Sozinibercept in treating wet AMD, with topline results expected in mid-2025. The trials aim to replicate the positive visual outcomes seen in Phase 2b.
The completion of enrollment in Phase 3 trials is a significant milestone for Opthea, indicating progress in their clinical development. Positive results could lead to regulatory approval and commercialization, potentially boosting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100